KLK3 and posterior cortical atrophy: Early diagnosis and stratified management of PCa are essential to improve patient prognosis, in which serum prostate-specific antigen (PSA) test has been a core biomarker for PCa screening and diagnosis since its first clinical application in 1986, which can detect early PCa and reduce the risk of PCa (2, 3).